Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.51 |
| ▸ | CCND1 | P24385 | 6/20 | 0.51 |
| ▸ | CCND3 | P30281 | 5/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.51 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111515 | 0.84 | CDK4 (0.57) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112736 | 0.83 | CDK4 (0.72) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL27897985 | 0.83 | ALDH1A1 (0.36) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112592 | 0.82 | CDK4 (0.63) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112177 | 0.82 | CDK4 (0.75) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL27880987 | 0.81 | CDK4 (0.52) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL114117 | 0.80 | CDK4 (0.78) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL28799660 | 0.80 | CDK4 (0.62) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL110796 | 0.79 | MAP4K4 (0.48) | MAP4K4PDE10A | |
| SCHEMBL113839 | 0.79 | CDK4 (0.50) | CDK4CCND1CCND3CDK6CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| CN-102803225-A | Imidazole derivatives and their use as modulators of cyclin dependent kinases | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2424843-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | CDK4 13/4885CCND1 30/4885CCND3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.